



Perma-Fix Medical Provides Business Update

Wrocław – May 15, 2018 – Perma-Fix Medical S.A. (WAR: PFM) today provided a general business update for the first quarter ended March 31, 2018.

Dr Louis Centofanti, Chief Executive Officer of Perma-Fix Medical S.A stated, “We have significantly reduced our expenses versus the same time last year, as we decided to focus on an international partnering strategy, which we believe will provide us a more cost-effective path to market. Initially, we are focusing on smaller markets, such as Italy and Canada, where we have identified partners and the regulatory costs are much lower.”

About Perma-Fix Medical

Perma-Fix Medical S.A. was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszewska or David K. Waldman
Crescendo Communications, LLC
Tel: (+48) 693 354 580
Email : pfm@crescendo-ir.com